Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
By Li Guo, L. Ren, Siyuan Yang, M. Xiao, De Chang, Fan Yang, C. D. Dela Cruz, Yingying Wang, Chao Wu, Yan Xiao and 12 more. Clinical Infectious Diseases, 2020
1,444 citations recorded by the source corpus.
Abstract Background The emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. The current method of detection involves a quantitative polymerase chain reaction (qPCR)–based technique, which identifies the viral nucleic acids when present in sufficient quantity. False-negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19. Methods The host humoral response against SARS-CoV-2, including IgA, IgM, and IgG response, was examined by using an ELISA-based assay on the recombinant viral nucleocapsid protein. 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but with typical manifestation). The diagnostic value of IgM was evaluated in this cohort. Results The median duration of IgM and IgA antibody detection was 5 (IQR, 3–6) days, while IgG was detected 14 (IQR, 10–18) days after symptom onset, with a positive rate of 85.4%, 92.7%, and 77.9%, respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combining IgM ELISA assay with PCR for each patient compared with a single qPCR test (51.9%). Conclusions The humoral response to SARS-CoV-2 can aid in the diagnosis of COVID-19, including subclinical cases.
Subfields: Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/eebdda26bbc91ab75767a1c3650a1f7639e51d89
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 (2020, background): “However, there are still many questions regarding the significance of antibodies against the different viral proteins, and the cross reactivity of antibodies against other highly prevalent alpha- and beta-coronavirus, although it seems that cross reactivity occurs mostly within the beta-coronavirida”
- Deployment of convalescent plasma for the prevention and treatment of COVID-19. (2020, neutral): “While data are limited, seroconversion has been observed to occur between 8 and 21 days after the onset of symptoms (28, 30).”
- A Review of SARS-CoV-2 and the Ongoing Clinical Trials (2020, background): “Thus, it was proposed that IgM ELISA assay can be combined with PCR to enhance the detection sensitivity [40].”